Base-modified thymidines capable of terminating DNA synthesis are novel bioactive compounds with activity in cancer cells.
Ontology highlight
ABSTRACT: Current FDA-approved chemotherapeutic antimetabolites elicit severe side effects that warrant their improvement; therefore, we designed compounds with mechanisms of action focusing on inhibiting DNA replication rather than targeting multiple pathways. We previously discovered that 5-(α-substituted-2-nitrobenzyloxy)methyluridine-5'-triphosphates were exquisite DNA synthesis terminators; therefore, we synthesized a library of 35 thymidine analogs and evaluated their activity using an MTT cell viability assay of MCF7 breast cancer cells chosen for their vulnerability to these nucleoside derivatives. Compound 3a, having an α-tert-butyl-2-nitro-4-(phenyl)alkynylbenzyloxy group, showed an IC50 of 9±1μM. The compound is more selective for cancer cells than for fibroblast cells compared with 5-flu
SUBMITTER: Borland KM
PROVIDER: S-EPMC4380762 | biostudies-literature | 2015 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA